Cita APA

Wirth, L. J., Brose, M. S., Hoff, A., Hu, M., Capdevila Castillon, J., & Elisei, R. (2022). LIBRETTO-531: A phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.

Citación estilo Chicago

Wirth, Lori J., Marcia S. Brose, Ana Hoff, Mimi Hu, Jaume Capdevila Castillon, y Rossella Elisei. LIBRETTO-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-naïve RET-mutant Medullary Thyroid Cancer. 2022.

Cita MLA

Wirth, Lori J., et al. LIBRETTO-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-naïve RET-mutant Medullary Thyroid Cancer. 2022.